Generate Biomedicines, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
other
SEC Category
Emerging growth company
State of Incorporation
DE
Business Address
101 SOUTH STREET, SUITE 900, SOMERVILLE, MA, 02143
Mailing Address
101 SOUTH STREET, SUITE 900, SOMERVILLE, MA, 02143
Phone
888-469-0055
Fiscal Year End
1231
EIN
831630228
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 3 Initial insider ownership report | March 12, 2026 | View on SEC |
| 4 Insider stock transaction report | March 6, 2026 | View on SEC |
| 4 Insider stock transaction report | March 2, 2026 | View on SEC |
| 4 Insider stock transaction report | March 2, 2026 | View on SEC |
| 4 Insider stock transaction report | March 2, 2026 | View on SEC |
| 4 Insider stock transaction report | March 2, 2026 | View on SEC |
| 4 Insider stock transaction report | March 2, 2026 | View on SEC |
| 4 Insider stock transaction report | March 2, 2026 | View on SEC |
| 4 Insider stock transaction report | March 2, 2026 | View on SEC |
| 4 Insider stock transaction report | March 2, 2026 | View on SEC |
IPO Filings
S-1
February 4, 2026
- Pioneering AI-powered platform for de novo drug design, aiming to accelerate and improve drug discovery.
- Advanced three AI-designed drugs into human clinical testing, including one in late-stage (Phase 3) trials for severe asthma.
Insider Trading
STRONG BUY
5 insiders
12 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.